Unprecedented Effects of Achiral Oxazolidinones on Enantioselective Radical-Mediated Conjugate Additions Using a Chiral Zinc Triflate
摘要:
[GRAPHICS]A role of achiral oxazolidinones to enhance the enantioselectivity in reactions of N-cinnamoyloxazolidinones with alkyl radicals promoted by a chiral Lewis acid Is described. Efficient enantioselective radical-mediated conjugate additions of N-cinnamoyloxazolidinone can be realized by use of a chiral zinc triflate generated from a readily prepared chiral bisoxazoline and an achiral oxazolidinone. The NH moiety of achiral oxazolidinones is found to be necessary to enhance the enantioselectivity.
Unprecedented Effects of Achiral Oxazolidinones on Enantioselective Radical-Mediated Conjugate Additions Using a Chiral Zinc Triflate
摘要:
[GRAPHICS]A role of achiral oxazolidinones to enhance the enantioselectivity in reactions of N-cinnamoyloxazolidinones with alkyl radicals promoted by a chiral Lewis acid Is described. Efficient enantioselective radical-mediated conjugate additions of N-cinnamoyloxazolidinone can be realized by use of a chiral zinc triflate generated from a readily prepared chiral bisoxazoline and an achiral oxazolidinone. The NH moiety of achiral oxazolidinones is found to be necessary to enhance the enantioselectivity.
Oxazolidinones as .alpha..sub.1A receptor antagonists
申请人:Synaptic Pharmaceutical Corporation
公开号:US06159990A1
公开(公告)日:2000-12-12
This invention is directed to oxazolidinone compounds which are selective antagonists for human .alpha..sub.1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the .alpha..sub.1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.
including the particularly simple divinylglycine, which is not easily accessible by using conventional methods. A straightforwardsynthesis of symmetrically α,α-disubstituted α-amino acids is presented. The key step of this process relies on the efficient double addition of Grignard reagents to acyl cyanohydrins to provide N-acyl amino alcohols selectively in good yields. The chemoselectivity of the reaction
Dynamic Kinetic Resolution Processes Based on the Switchable Configurational Instability of Allenyl Copper Reagents
作者:Chayma Ben Maamer、Pierre C. Mpawenayo、Baptiste Lecachey、Nacira Alouane、Pierre Mangeney、Arie van der Lee、Jérôme Marrot、Samira Bouaouli、Maya Guillaumont、Rafâa Besbes、Hélène Gerard、Emmanuel Vrancken、Jean-Marc Campagne
DOI:10.1021/acs.orglett.1c02095
日期:2021.8.20
the configurational stability of allenyl copper reagents. A judicious choice of the reaction conditions allows efficient dynamickineticresolution processes and gives a one-pot access to homopropargylic alcohols or amines bearing up to four contiguous defined stereogeniccenters.
揭示了烯基铜试剂的构型不稳定性。一项实验研究强调了 Li +和反应温度在控制丙二烯基铜试剂构型稳定性方面的关键作用。反应条件的明智选择允许有效的动态动力学拆分过程,并提供一锅法获得带有多达四个连续定义的立体中心的高炔醇或胺。
Temperature dependent reversal of stereochemistry in enantioselective conjugate amine additions
作者:Mukund P Sibi、Uma Gorikunti、Mei Liu
DOI:10.1016/s0040-4020(02)00988-2
日期:2002.10
Enoates derived from 4,4-disubstituted-2-oxazolidinones undergo enantioselective conjugate amineaddition when mediated by a chiral Lewis acid derived from magnesium bromide and a bisoxazoline. The face selectivity in these amineadditions is temperature dependent. They show an unusual reversal at two different temperatures.
[EN] HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF<br/>[FR] PIPERIDINES A SUBSTITUTION HETEROCYCLIQUE ET UTILISATIONS DE CES DERNIERES
申请人:SYNAPTIC PHARMACEUTICAL CORPORATION
公开号:WO1998057940A1
公开(公告)日:1998-12-23
(EN) This invention is directed to oxazolidinone compounds which are selective antagonists for human $g(a)1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the $g(a)1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.(FR) Cette invention concerne des composés d'oxazolidinone qui sont des antagonistes sélectifs des récepteurs $g(a)1A humains. Cette invention concerne également les différentes utilisations de ces composés pour réduire la pression intra-oculaire, empêcher la synthèse du cholestérol, détendre les tissues du tractus urinaire inférieur, traiter l'hyperplasie prostatique bénigne, l'impuissance, l'arythmie cardiaque et pour traiter toute maladie dans laquelle l'antagoniste du récepteur $g(a)1A peut être utile. Cette invention concerne également une composition pharmaceutique contenant une quantité thérapeutiquement efficace des composés présentés ci-avant ainsi qu'un support pharmaceutiquement acceptable.